Supplementary Figure 4 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
crossref(2024)
Supplementary Figure 4: Pre-existing immune condition prior to denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, NKG2D, OX40, PD-1, PD-L1, PD-L2, TIGIT and TIM3 when comparing patients who did not receive chemotherapy or steroids with patients that received chemotherapy, steroids, or both at pretreatment TP1. Each box in the heatmap represents a lymphocyte cluster that was labeled according to the nearest landmark node they connect to on the scaffold map and ordered by cell count abundance. The pseudocolor represents clusters that showed a significant difference (q<0.05) in the log2 fold change, with red being significantly higher, while blue being significantly lower in group 2 of the two comparison groups.